Latest Conference Articles

Experts explore innovative therapies for high-risk smoldering multiple myeloma, aiming to delay progression and enhance patient outcomes through early intervention.

Daratumumab-based regimens show significant clinical benefits for newly diagnosed, transplant-ineligible multiple myeloma patients, regardless of frailty changes.

Paula Rodriguez Otero, MD, PhD, discusses promising results of linvoseltamab in high-risk smoldering multiple myeloma, highlighting its potential to prevent disease progression.

Paula Rodriguez Otero, MD, PhD, discusses linvoseltamab's manageable safety profile in high-risk smoldering multiple myeloma, highlighting promising study results.

A phase 2 study evaluates linvoseltamab's safety and efficacy in high-risk smoldering myeloma, focusing on response rates and MRD negativity.

Experts explore the evolving treatment strategies for high-risk smoldering multiple myeloma, highlighting studies that show early intervention can improve patient outcomes.

Research explores innovative treatments for high-risk smoldering multiple myeloma, highlighting promising results from the bispecific antibody linvoseltamab.

New findings reveal tarlatamab combined with anti–PD-L1 agents significantly improves survival in extensive-stage small cell lung cancer, prompting further research.

A new subcutaneous formulation of amivantamab shows high efficacy and improved safety for advanced NSCLC patients, enhancing treatment convenience.

The COCOON study reveals a new dermatology management strategy that significantly reduces skin-related adverse effects in patients with lung cancer patients undergoing treatment with amivantamab and lazertinib.

ABBV-706 shows promising efficacy and manageable safety in relapsed/refractory small cell lung cancer, offering hope for heavily treated patients.

Firmonertinib shows significant antitumor activity in EGFR PACC-mutated NSCLC, with promising results in CNS penetration and manageable safety profiles.

Ifinatamab deruxtecan shows promising antitumor activity in extensive-stage small cell lung cancer, with high response rates and durable outcomes.

Osimertinib combined with chemotherapy significantly enhances overall survival in advanced EGFR-mutated non-small cell lung cancer, according to FLAURA2 trial results.

Anita Turk, MD, discusses abstracts from ASCO 2025 highlight the evolving role of ctDNA in the management of colorectal cancer.

Discover groundbreaking advancements in GI cancer treatments from ASCO 2025, highlighting innovative therapies and improved patient outcomes.

Arturo Loaiza-Bonilla, MD, MSEd, discusses 5-year data from the phase 3 CheckMate 577 trial, presented at the 2025 ASCO Annual Meeting.

The QUILT-88 study reveals promising survival rates for advanced pancreatic cancer patients using a multimodal treatment approach, combining chemotherapy and immunotherapy.

Arturo Loaiza-Bonilla, MD, MSEd, discusses the potential of disitamab vedotin, toripalimab, and chemotherapy/trastuzumab in first-line treatment.

Arturo Loaiza-Bonilla, MD, MSEd, discusses findings from the MATTERHORN trial in patients with resectable gastric or gastroesophageal junction adenocarcinoma.

Dale Shepard, MD, PhD, discusses the key themes emerging from the 2025 ASCO Annual Meeting, highlighting a prevailing sense of optimism driven by ongoing research.

Erika Hamilton, MD, shares key insights from the 2025 ASCO Annual Meeting that are set to impact breast cancer treatment.

Shahzad Raza, MD, discusses new data from the phase 2 RedirecTT-1 study of talquetamab with teclistamab for the treatment of patients with relapsed/refractory multiple myeloma and extramedullary disease.

The STELLAR-002 study reports promising efficacy and manageable safety for zanzalintinib plus nivolumab in untreated stage 4 RCC patients.

Pembrolizumab consistently improves overall and disease-free survival in clear cell renal cell carcinoma, showing sustained benefit at 5 years post surgery.

Combining sasanlimab with BCG significantly enhances event-free survival in high-risk non-muscle invasive bladder cancer, especially in CIS patients.

A groundbreaking trial explores pembrolizumab's role in enhancing treatment outcomes for advanced head and neck cancer, promising significant advancements in patient care.